Comparing biote (NASDAQ:BTMD) & Elevance Health (NYSE:ELV)

biote (NASDAQ:BTMD) and Elevance Health (NYSE:ELV) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for biote and Elevance Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	1	2.50
Elevance Health	0	7	15	0	2.68

biote presently has a consensus price target of $2.50, suggesting a potential upside of 134.74%. Elevance Health has a consensus price target of $456.48, suggesting a potential upside of 6.28%. Given biote’s higher possible upside, equities analysts plainly believe biote is more favorable than Elevance Health.

Risk and Volatility

biote has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Elevance Health has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Profitability

This table compares biote and Elevance Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	-1.08%	-8.61%	4.61%
Elevance Health	2.55%	14.97%	5.31%

Valuation and Earnings

This table compares biote and Elevance Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22 million	0.20	$27.05 million	($0.10)	-10.65
Elevance Health	$201.83 billion	0.46	$5.66 billion	$23.45	18.32

Elevance Health has higher revenue and earnings than biote. biote is trading at a lower price-to-earnings ratio than Elevance Health, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

21.7% of biote shares are held by institutional investors. Comparatively, 89.2% of Elevance Health shares are held by institutional investors. 32.4% of biote shares are held by insiders. Comparatively, 0.3% of Elevance Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Elevance Health beats biote on 11 of the 15 factors compared between the two stocks.

About biote

Biote is a medical technology and services company focused on hormone optimization. It supports healthcare providers who offer bioidentical hormone replacement therapy (BHRT), including pellet-based treatment programs for eligible patients. The company’s services include provider training and education, patient and practice support, and hormone testing and treatment protocols. Biote also offers nutritional supplements and related wellness products through participating providers. Biote was founded in 2012 and serves a network of healthcare providers in the United States.

About Elevance Health

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.